{
    "2019-05-10": [
        [
            {
                "time": "",
                "original_text": "定增请进来，成本价赶出去！药明康德教你怎么对PE过河拆桥",
                "features": {
                    "keywords": [
                        "定增",
                        "药明康德",
                        "PE",
                        "过河拆桥"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "药明康德：控股子公司拟申请从新三板终止挂牌，并已被受理 关联方问题",
                "features": {
                    "keywords": [
                        "药明康德",
                        "新三板",
                        "终止挂牌",
                        "关联方"
                    ],
                    "sentiment_score": -0.3,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "药明康德(02359.HK)旗下合全药业终止新三板挂牌 退市",
                "features": {
                    "keywords": [
                        "药明康德",
                        "合全药业",
                        "新三板",
                        "退市"
                    ],
                    "sentiment_score": -0.4,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "港股异动︱药明康德涨逾6% 收购美国临床研究服务公司Pharmapace",
                "features": {
                    "keywords": [
                        "药明康德",
                        "港股",
                        "收购",
                        "Pharmapace"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "港股异动︱此前获小摩看高至115元评级“增持” 药明康德(02359)反弹超7%",
                "features": {
                    "keywords": [
                        "药明康德",
                        "港股",
                        "小摩",
                        "增持",
                        "反弹"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}